We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SGHT Shares Rise on Meta-Analysis Showing OMNI's Long-Term Benefits
Read MoreHide Full Article
Key Takeaways
{\"0\":\"SGHT announced a published meta-analysis validating OMNI\'s long-term safety and efficacy.\",\"1\":\"SGHT\'s OMNI was shown to reduce IOP and medication use with durable outcomes.\",\"2\":\"SGHT reported that nearly 89% of patients achieved at least 20% IOP reduction at 6, 12 and 24 months.\"}
Sight Sciences (SGHT - Free Report) recently announced the publication of a systematic literature review and meta-analysis in the European Journal of Ophthalmology, highlighting the long-term safety and efficacy of the OMNI Surgical System (OMNI). The review confirmed that OMNI delivers clinically significant reductions in intraocular pressure (IOP) and medication use for patients with primary open-angle glaucoma.
The findings reinforce OMNI’s position as a strong treatment option, with favorable safety outcomes and durability that may delay the need for more invasive procedures. Positive clinical evidence like this not only strengthens surgeon confidence but also supports payer reimbursement decisions, underscoring the system’s potential to drive adoption and growth for SGHT.
Likely Trend of SGHT Stock Following the News
Following the announcement, the company's shares gained 7.9% yesterday and closed at $3.69. Shares of the company have gained 1.4% in the year-to-date period against the industry’s 11.4% decline. The S&P 500 has gained 13.3% in the same time frame.
This latest meta-analysis strengthens the case for Sight Sciences in the long run by reinforcing the OMNI Surgical System’s proven safety, durability and cost-effectiveness. Strong peer-reviewed evidence builds surgeon confidence, supports payer reimbursement and highlights OMNI’s ability to reduce reliance on medications and delay more invasive procedures. Together, these factors can drive broader adoption, position SGHT competitively in the growing Minimally Invasive Glaucoma Surgery market and support sustainable revenue growth.
SGHT currently has a market capitalization of $179.1 million. The company projects an earnings growth of 17.7% for the next year.
Image Source: Zacks Investment Research
More on SGHT's Meta-Analysis Study for OMNI
Glaucoma is the leading cause of irreversible blindness, with many patients dependent on lifelong medications or invasive surgeries to manage IOP. These options can be costly, burdensome and not always effective, creating a need for less invasive, durable treatments that reduce medication reliance and delay more aggressive procedures.
The newly published meta-analysis directly addresses this gap by evaluating the effectiveness, safety and economic impact of the OMNI and its predecessors. Covering 29 publications across 22 unique studies and 2,379 eyes, the study concluded that OMNI offers sustained reductions in IOP and medication use while maintaining a favorable safety profile. By validating OMNI’s performance in both standalone and combination treatments, the findings underscore its role as a reliable option for patients with primary open-angle glaucoma.
Key Study Findings
The analysis revealed that treatment success, defined as a reduction in IOP of at least 20% from baseline, was achieved in nearly 89% of patients at six, 12 and 24 months. After six and 12 months, approximately 66–68% of patients treated with either standalone or combined treatments remained medication-free, a meaningful outcome that highlights OMNI’s ability to improve quality of life while reducing the long-term treatment burden. These results demonstrate the durability of OMNI’s impact, which can help slow disease progression and preserve vision.
Beyond clinical outcomes, the study also confirmed OMNI’s economic value compared with the leading market alternative, iStent inject. The cost-utility analysis included quality of life outcomes in the form of quality-adjusted life years (QALYs). Patients treated with OMNI achieved an average of 8.95 QALYs over a lifetime horizon and 1.59 over two years, compared with 8.93 and 1.58, respectively, for iStent inject. The slightly higher QALYs for OMNI were attributed to its favorable adverse event profile.
SGHT’s Zacks Rank & Key Picks
Currently, SGHT carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are West Pharmaceutical Services, Inc. (WST - Free Report) , Medpace Holdings, Inc. (MEDP - Free Report) and Envista (NVST - Free Report) .
West Pharmaceutical reported second-quarter 2025 adjusted earnings per share (EPS) of $1.84, which beat the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the consensus estimate by 5.4%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Medpace Holdings, sporting a Zacks Rank of 1 at present, reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
Envista reported second-quarter 2025 adjusted EPS of 26 cents, which beat the Zacks Consensus Estimate by 8.3%. Revenues of $682 million surpassed the consensus estimate by 6.3%. It currently carries a Zacks Rank #2 (Buy).
Envista has a long-term estimated growth rate of 16.8%. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.50%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
SGHT Shares Rise on Meta-Analysis Showing OMNI's Long-Term Benefits
Key Takeaways
Sight Sciences (SGHT - Free Report) recently announced the publication of a systematic literature review and meta-analysis in the European Journal of Ophthalmology, highlighting the long-term safety and efficacy of the OMNI Surgical System (OMNI). The review confirmed that OMNI delivers clinically significant reductions in intraocular pressure (IOP) and medication use for patients with primary open-angle glaucoma.
The findings reinforce OMNI’s position as a strong treatment option, with favorable safety outcomes and durability that may delay the need for more invasive procedures. Positive clinical evidence like this not only strengthens surgeon confidence but also supports payer reimbursement decisions, underscoring the system’s potential to drive adoption and growth for SGHT.
Likely Trend of SGHT Stock Following the News
Following the announcement, the company's shares gained 7.9% yesterday and closed at $3.69. Shares of the company have gained 1.4% in the year-to-date period against the industry’s 11.4% decline. The S&P 500 has gained 13.3% in the same time frame.
This latest meta-analysis strengthens the case for Sight Sciences in the long run by reinforcing the OMNI Surgical System’s proven safety, durability and cost-effectiveness. Strong peer-reviewed evidence builds surgeon confidence, supports payer reimbursement and highlights OMNI’s ability to reduce reliance on medications and delay more invasive procedures. Together, these factors can drive broader adoption, position SGHT competitively in the growing Minimally Invasive Glaucoma Surgery market and support sustainable revenue growth.
SGHT currently has a market capitalization of $179.1 million. The company projects an earnings growth of 17.7% for the next year.
Image Source: Zacks Investment Research
More on SGHT's Meta-Analysis Study for OMNI
Glaucoma is the leading cause of irreversible blindness, with many patients dependent on lifelong medications or invasive surgeries to manage IOP. These options can be costly, burdensome and not always effective, creating a need for less invasive, durable treatments that reduce medication reliance and delay more aggressive procedures.
The newly published meta-analysis directly addresses this gap by evaluating the effectiveness, safety and economic impact of the OMNI and its predecessors. Covering 29 publications across 22 unique studies and 2,379 eyes, the study concluded that OMNI offers sustained reductions in IOP and medication use while maintaining a favorable safety profile. By validating OMNI’s performance in both standalone and combination treatments, the findings underscore its role as a reliable option for patients with primary open-angle glaucoma.
Key Study Findings
The analysis revealed that treatment success, defined as a reduction in IOP of at least 20% from baseline, was achieved in nearly 89% of patients at six, 12 and 24 months. After six and 12 months, approximately 66–68% of patients treated with either standalone or combined treatments remained medication-free, a meaningful outcome that highlights OMNI’s ability to improve quality of life while reducing the long-term treatment burden. These results demonstrate the durability of OMNI’s impact, which can help slow disease progression and preserve vision.
Beyond clinical outcomes, the study also confirmed OMNI’s economic value compared with the leading market alternative, iStent inject. The cost-utility analysis included quality of life outcomes in the form of quality-adjusted life years (QALYs). Patients treated with OMNI achieved an average of 8.95 QALYs over a lifetime horizon and 1.59 over two years, compared with 8.93 and 1.58, respectively, for iStent inject. The slightly higher QALYs for OMNI were attributed to its favorable adverse event profile.
SGHT’s Zacks Rank & Key Picks
Currently, SGHT carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are West Pharmaceutical Services, Inc. (WST - Free Report) , Medpace Holdings, Inc. (MEDP - Free Report) and Envista (NVST - Free Report) .
West Pharmaceutical reported second-quarter 2025 adjusted earnings per share (EPS) of $1.84, which beat the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the consensus estimate by 5.4%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Medpace Holdings, sporting a Zacks Rank of 1 at present, reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
Envista reported second-quarter 2025 adjusted EPS of 26 cents, which beat the Zacks Consensus Estimate by 8.3%. Revenues of $682 million surpassed the consensus estimate by 6.3%. It currently carries a Zacks Rank #2 (Buy).
Envista has a long-term estimated growth rate of 16.8%. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.50%.